John Strafford - Silence Therapeutics Alliance Devel
| SLN Stock | USD 7.67 0.21 2.82% |
Insider
John Strafford is Alliance Devel of Silence Therapeutics PLC
| Address | 72 Hammersmith Road, London, United Kingdom, W14 8TH |
| Phone | 44 20 3457 6900 |
| Web | https://www.silence-therapeutics.com |
Silence Therapeutics Management Efficiency
The company has Return on Asset of (0.2154) % which means that on every $100 spent on assets, it lost $0.2154. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6428) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Silence Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 29th of November 2024, Asset Turnover is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 8.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| James JD | Eliem Therapeutics | 58 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Quinn Deveraux | Inhibrx | N/A | |
| JD MSc | Cue Biopharma | 61 | |
| BS CPA | Inhibrx | 42 | |
| Mark Lappe | Inhibrx | 57 | |
| Dr III | Cue Biopharma | 48 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Kenneth MD | Cue Biopharma | 64 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.22 |
Silence Therapeutics PLC Leadership Team
Elected by the shareholders, the Silence Therapeutics' board of directors comprises two types of representatives: Silence Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silence. The board's role is to monitor Silence Therapeutics' management team and ensure that shareholders' interests are well served. Silence Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silence Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Strafford, Alliance Devel | ||
| Rhonda Hellums, Chief Officer | ||
| Eric Floyd, VP Assurance | ||
| Gem Hopkins, Head Communications | ||
| Gianine Esposito, Chief Officer | ||
| Giles MD, Head VP | ||
| Jrgen Wittendorff, VP Manufacturing | ||
| Craig MBA, President Officer | ||
| Steven MD, Executive Officer | ||
| J Gabriel, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| Marie Lindholm, Chief Officer | ||
| Dr JD, Senior Officer | ||
| Curtis MD, Chief Officer | ||
| MBA MS, Senior Assurance |
Silence Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silence Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.24) % | ||||
| Operating Margin | (30.64) % | ||||
| Current Valuation | 192.11 M | ||||
| Shares Outstanding | 47.21 M | ||||
| Shares Owned By Insiders | 16.93 % | ||||
| Shares Owned By Institutions | 62.70 % | ||||
| Number Of Shares Shorted | 381.47 K | ||||
| Price To Book | 3.05 X |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Silence Stock
| 0.8 | VTRS | Viatris | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.7 | ESPR | Esperion Therapeutics | PairCorr |
| 0.46 | BFRIW | Biofrontera Warrants | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.